Eli Lilly Alzheimer's treatment solanezumab failed to slow disease progression
March 08, 2023 at 23:34 PM EST
Solanezumab's failure is a blow to efforts to treat Alzheimer's in people who have not yet shown clinical symptoms.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|